CYTOMEL by Meditech is a pharmaceutical-grade oral Liothyronine Sodium (T3) formulation at 25 mcg per tablet, supplied in sachets of 100 tablets or blister packs of 2 × 50 tablets. Liothyronine sodium is a synthetic form of triiodothyronine — the biologically active thyroid hormone — with an established research history in endocrinological and metabolic medicine literature. As the direct-acting form of thyroid hormone requiring no peripheral conversion prior to receptor binding, liothyronine is documented in comparative thyroid pharmacology research for its more rapid onset and pronounced metabolic activity relative to levothyroxine (T4)-based preparations.
 
✔ Key Research Insights
Studied for its direct thyroid hormone receptor binding activity in research subjects, bypassing the peripheral T4-to-T3 conversion step required by levothyroxine, with documented rapid elevation of metabolic rate and thermogenic activity in clinical observations
Investigated for its influence on basal metabolic rate, caloric oxidation efficiency, and fat utilization parameters across documented subject populations in metabolic research literature
Researched for its effects on body composition indices during caloric deficit protocols, with documented influences on fat metabolism while lean mass preservation parameters have been examined in comparative thyroid hormone research
Examined for its rapid-onset pharmacokinetic profile relative to levothyroxine, with peak plasma T3 concentrations and metabolic activity documented within a compressed timeframe in comparative thyroid hormone pharmacokinetic research
Documented for the clinical relevance of graduated dosing protocols — referenced as pyramid dosing approaches in research literature — associated with minimized thyroid axis disruption and more controlled metabolic rate adjustment in documented administration protocols
Researched for its suppressive effects on endogenous thyroid hormone production via hypothalamic-pituitary-thyroid axis feedback inhibition, with post-administration thyroid function restoration considerations referenced in clinical literature
Manufactured by Meditech to pharmaceutical-grade purity and consistent potency standards
 
📦 Product Specifications
Manufacturer: Meditech
Product: CYTOMEL
Molecule: Liothyronine Sodium (Synthetic T3)
Concentration: 25 mcg per tablet
Appearance: Red octagon-shaped tablet imprinted with logo "M"
Packing: 100 tablets per sachet or 2 × 50 tablet blister packs
Dosage considerations may vary. Consulting a qualified professional is recommended.
 
⚙ How It Works
Liothyronine sodium is a synthetic form of triiodothyronine (T3), the primary biologically active thyroid hormone at the receptor level. Unlike levothyroxine (T4), which requires peripheral enzymatic conversion to T3 — primarily in the liver and kidneys — prior to exerting biological activity, liothyronine binds directly to thyroid hormone receptors in target tissues following oral absorption in research subjects without requiring a prior conversion step. This direct receptor binding activity is associated in comparative thyroid pharmacology research with a more rapid onset of metabolic effects and more pronounced thermogenic activity per microgram relative to T4-based preparations. At the cellular level, T3 receptor binding regulates gene transcription pathways governing basal metabolic rate, mitochondrial thermogenesis, protein synthesis, and lipid mobilization — with documented effects on increased caloric oxidation and fat substrate utilization in research subject populations. The administration of exogenous liothyronine suppresses endogenous thyroid hormone production via negative feedback on the hypothalamic-pituitary-thyroid (HPT) axis in research subjects, a pharmacological consideration referenced in clinical literature as necessitating careful dose management and graduated withdrawal protocols to support restoration of endogenous thyroid function following exogenous T3 administration. Pyramid dosing protocols — characterized by gradual dose escalation followed by gradual tapering — are referenced in comparative thyroid hormone research as a preferred administration strategy for minimizing thyroid axis disruption and associated rebound effects.
 
⭐ Product Overview
Manufactured by Meditech to pharmaceutical-grade purity and consistent potency standards
Direct-acting synthetic T3 formulation with a well-documented rapid-onset pharmacokinetic and thermogenic activity profile in comparative thyroid hormone research
Distinctively identified red octagon tablet presentation at 25 mcg per tablet supporting accurate and flexible dose titration across graduated dosing protocols
Available in both sachet and blister pack formats providing 100 tablets per unit, supporting extended research protocol administration
Widely referenced in endocrinological, metabolic, and thyroid pharmacology research literature under the liothyronine sodium, T3, and Cytomel designations